Cologuard
Exact Sciences Corporation · Decision date Nov 24, 2025
What did the FDA approve?
FDA records P130017/S066 as a supplement to PMA P130017, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 24, 2025.
FDA approval order statement
The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement, which qualified for review under the Real-Time Review Program. Your supplement requested to modify the in-process sample stability of the hemoglobin sample from 7 days to 14 days at 2 to 8°C, and additional minor labeling changes. Based upon the information submitted, the PMA supplement is approved. You may begin commercial distribution of the device as modified by your PMA supplement in accordance with the conditions described below. Although this letter refers to your product as a device, please be aware that some approved products may instead be combination products.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Pathology
- Decision date
- Nov 24, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P130017/S066
- Regulatory pathway
- PMA supplement
- Applicant
- Exact Sciences Corporation
- Product code
- PHP
- Decision code
- APPR
- Decision date
- Nov 24, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, colorectal neoplasia, DNA methylation and hemoglobin detection.
- Applicant
- Exact Sciences Corporation
- Product code
- PHP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P130017/S063 · Related supplement
Cologuard
P130017/S064 · Related supplement
Cologuard test
P130017/S066 received
Application receipt date recorded by FDA.
P130017/S065 · Related supplement
Cologuard
P130017/S066 · FDA decision
Real-Time Process
P130017/S067 · Related supplement
Cologuard
P130017/S069 · Related supplement
Cologuard
P130017/S068 · Related supplement
Cologuard
P130017/S070 · Related supplement
Cologuard
Timeline entries are records held by MedtechLedger for P130017. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130017
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CologuardP130017/S063 | Exact Sciences Corporation | PMA supplement | Jul 18, 2025 | FDA |
Cologuard testP130017/S064 | Exact Sciences Corporation | PMA supplement | Jul 24, 2025 | FDA |
CologuardP130017/S065 | Exact Sciences Corporation | PMA supplement | Oct 7, 2025 | FDA |
CologuardP130017/S067 | Exact Sciences Corporation | PMA supplement | Mar 13, 2026 | FDA |
CologuardP130017/S069 | Exact Sciences Corporation | PMA supplement | Apr 22, 2026 | FDA |
CologuardP130017/S068 | Exact Sciences Corporation | PMA supplement | May 27, 2026 | FDA |
CologuardP130017/S070 | Exact Sciences Corporation | PMA supplement | Jun 9, 2026 | FDA |
Explore the linked device profile
Other records with product code PHP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SimpleScreen CRCP250029/S003 | Freenome, LLC | PMA supplement | Oct 27, 2026 | FDA |
ShieldP230009/S021 | Guardant Health, Inc. | PMA supplement | Oct 5, 2026 | FDA |
ShieldP230009/S020 | Guardant Health, Inc. | PMA supplement | Sep 16, 2026 | FDA |
SimpleScreen CRCP250029/S001 | Freenome, LLC | PMA supplement | Aug 26, 2026 | FDA |
Cologuard PlusP230043/S010 | Exact Sciences Corporation | PMA supplement | Aug 3, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Exact Sciences Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 441 Charmany Dr., Medison, WI, 53719
Sources and methodology
- Original FDA record: P130017/S066
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





